Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year Low – Here’s Why

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) reached a new 52-week low on Wednesday. The company traded as low as $12.69 and last traded at $12.72, with a volume of 1,656,243 shares. The stock had previously closed at $14.29.

Key Syndax Pharmaceuticals News

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Syndax said 19 abstracts covering Revuforj (revumenib) and Niktimvo (axatilimab-csfr) were accepted for ASH 2026, including seven oral presentations. Revumenib data span several acute leukemia settings, while axatilimab abstracts include longer-term data in chronic graft-versus-host disease. The breadth of presentations may support investor confidence in the therapies’ potential. ASH abstracts announcement
• Positive Sentiment: Third-quarter revenue rose 82% year over year to $83.3 million, above analyst estimates. Revuforj revenue increased 90% to $60.7 million, with new patients up 20% sequentially; Niktimvo partner sales were $67.4 million, generating $22.6 million in Syndax collaboration revenue. Third-quarter results and business update
• Neutral Sentiment: Syndax appointed Aaron A. Ondrey CFO effective November 9. Current CFO Keith Goldan plans to retire but will remain through year-end to support the transition, indicating a planned handover. CFO transition announcement
• Neutral Sentiment: The company will hold an investor event during the ASH meeting on December 14, providing an opportunity to discuss its therapies and data, but no new results were announced with the event notice. ASH investor event announcement
• Negative Sentiment: Syndax’s quarterly loss of $0.55 per share was wider than the roughly $0.50 consensus estimate, despite the revenue beat and improvement from a year-earlier loss. Reports also cite pipeline setbacks as an overhang, tempering the commercial growth story. Earnings and pipeline concerns
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Syndax investors. The notice provides no specific findings, but adds legal uncertainty and headline risk. Investor investigation notice

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on SNDX shares. Mizuho set a $43.00 target price on Syndax Pharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. cut their price objective on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. Finally, HC Wainwright decreased their price target on Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.60.

Syndax Pharmaceuticals Stock Performance

The company has a fifty day moving average of $16.95 and a two-hundred day moving average of $20.18. The firm has a market capitalization of $936.61 million, a price-to-earnings ratio of -4.48 and a beta of 0.48. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 6.77.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.05). The business had revenue of $83.30 million during the quarter, compared to analyst estimates of $81.38 million. Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 517.88%. The company’s revenue was up 81.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.70) earnings per share. As a group, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $14.21, for a total transaction of $113,680.00. Following the transaction, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. This represents a 3.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SNDX. CenterBook Partners LP acquired a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter worth $5,137,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Syndax Pharmaceuticals during the third quarter worth $86,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Syndax Pharmaceuticals by 15.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,293 shares of the company’s stock valued at $297,000 after buying an additional 2,191 shares during the last quarter. Sterling Capital Management LLC raised its position in Syndax Pharmaceuticals by 846.6% during the third quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock valued at $56,000 after acquiring an additional 2,650 shares in the last quarter. Finally, Inspire Investing LLC increased its holdings in Syndax Pharmaceuticals by 10.2% in the third quarter. Inspire Investing LLC now owns 34,122 shares of the company’s stock valued at $641,000 after buying an additional 3,157 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.